About Dermagnostix
At Dermagnostix, we envision the next level for molecular diagnostics in human skin to improve patients' lives and clinical practice in dermatology.
Why Dermatology?
Dermatologic diseases are the 4th most common cause of all human illnesses.
Every individual experiences a skin disease at least once during their lifetime.
7 of the 15 best selling drugs are used in dermatology already today and many more promising treatments are in the pipeline.
Conventional Diagnostics
... based on clinical view and histopathology are imprecise and impede the optimal use of the already available highly specific modern therapies in dermatology.
The Solution
... is to offer modern diagnostics for modern therapies. With our first test – PsorEx – to differentiate between eczema and psoriasis on molecular level we achieved a milestone for molecular diagnostics in dermatology.
Dermagnostix offers a comprehensive technological platform for fast and objective molecular diagnostics in dermatology to reduce health care costs and improve patient treatment.
Dermagnostix provides molecular diagnostic solution for dermatology - economic, fast, easy and precise.
- Founding: 2021
- Focus : Manufacturer
- Industry : Diagnostics
Product portfolio of Dermagnostix
News about Dermagnostix
Here you will find Dermagnostix GmbH
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
